Company / R&D Expense
Cullinan Therapeutics, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$142.9M
FY2024
5-year range
$43.2M / $148.2M
FY2020-FY2024
Trend
-3.5%
vs FY2023
Sector context
#108 of 210
Health Care
What the data says
At $143M, Cullinan Therapeutics, Inc.'s r&d expense ranks #108 of 210 in the Health Care sector. Improved from $92M to $143M over the past 2 years.
Based on SEC 10-K filings.
$143M in FY2024 with a 3-year CAGR of +49.0%.
Improved from $92M to $143M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +49.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#108 of 210 in Health CareTop 51% of 210This company $142.9M Sector average $644.0M
▼
-77.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +49.0%, indicating consistent growth.
- In FY2024, r&d expense decreased 3.5% year-over-year.
- Ranks #108 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $142.9M | -3.5% |
| FY2023 | $148.2M | +61.1% |
| FY2022 | $91.9M | +112.8% |
| FY2021 | $43.2M | +0.0% |
| FY2020 | $43.2M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026